Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: Insights from the EPIC, EPILOG, and EPISTENT trials

Heart

Volumn 89, Issue 10, 2003, Pages 1200-1204

  Gurm, H S ^a   Bhatt, D L ^a   Lincoff, A M ^a   Tcheng, J E ^b   Kereiakes, D J ^c   Kleiman, N S ^d   Jia, G ^a   Topol, E J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c The Carl & Edyth Lindner Center for Research & Education   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; HEPARIN;

ARTICLE; ATHERECTOMY; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; DEATH; DEVICE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENDER; HAZARD; HEART INFARCTION; HEART RATE; HUMAN; INCIDENCE; ISCHEMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SURGICAL MORTALITY; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0141455899     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.89.10.1200     Document Type: Article

References (34)

1. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation 2002;106:136-40.
2. Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994;331:468-9.
3. Baker IA, Pickering J, Elwood PC, et al. Fibrinogen, viscosity and white blood cell count predict myocardial, but not cerebral infarction: evidence from the Caerphilly and Speedwell cohort. Thromb Haemost 2002;87:421-5.
4. Barron HV, Cannon CP, Murphy SA, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 2000;102:2329-34.
5. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-60.
6. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104:992-7.
7. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-21.
8. de Labry LO, Campion EW, Glynn RJ, et al. White blood cell count as a predictor of mortality: results over 18 years from the Normative Aging Study. J Clin Epidemiol 1990;43:153-7.
9. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477-82.
10. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.
11. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
12. Yarnell JW, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991;83:836-44.
13. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
14. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
15. Folsom AR, Wu KK, Rosamond WD, et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Circulation 1997;96:1102-8.
16. Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease. Insights from the Framingham Study. JAMA 1992;267:1253-6.
17. Brown DW, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol 2001;54:316-22.
18. Cannon CP, McCabe CH, Wilcox RG, et al. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 investigators. Am J Cardiol 2001;87:636-9, A10.
19. Furman MI, Becker RC, Yarzebski J, et al. Effect of elevated leukocyte count on in-hospital mortality following acute myocardial infarctian. Am J Cardiol 1996;78:945-8.
20. Prentice RL, Szatrowski TP, Fujikura T, et al. Leukocyte counts and coronary heart disease in a Japanese cahort. Am J Epidemiol 1982;116:496-509.
21. Weijenberg MP, Feskens EJ, Kromhout D. White blood cell count and the risk of coronary heart disease and all-cause mortality in elderly men. Arterioscler Thromb Vasc Biol 1996;16:499-503.
22. Gurm H, Gupta R, Lauer M, et al. The baseline leucocyte count is a strong and independent predictor of mortality in patients undergoing percutaneous coronary artery interventions: implications of arterial inflammation [abstract]. Circulation 2001;104:II775.
23. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein llb/Illa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl J Med 1994;330:956-61.
24. EPILOG Investigators. Platelet glycoprotein llb/Illa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96.
25. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- llb/Illa blockade. The EPISTENT investigators. Evaluation of platelet llb/Illa inhibitor for stenting. Lancet 1998;352:87-92.
26. Sweetnam PM, Thomas HF, Yarnell JW, et al. Total and differential leukocyte counts as predictors of ischemic heart disease: the Caerphilly and Speedwell studies. Am J Epidemiol 1997;145:416-21.
27. Serrano CV Jr, Ramires JA, Venturinelli M, et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol 1997;29:1276-83.
28. Mickelson JK, Lakkis NM, Villarreal-Levy G, et al. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol 1996;28:345-53.
29. Ikeda H, Nakayama H, Oda T, et al. Neutrophil activation after percutaneous transluminal coronary angioplasty. Am Heart J 1994;128:1091-8.
30. Pietersma A, Kofflard M, de Wit LE, et al. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation 1995;91:1320-5.
31. Spooner PM, Zipes DP. Sudden death predictors: an inflammatory association. Circulation 2002;105:2574-6.
32. Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002;105:2595-9.
33. Lauer MS, Blackstone EH, Young JB, et al. Cause of death in clinical research: time for a reassessment? J Am Coll Cardiol 1999;34:618-20.
34. Pellizzon GG, Dixon SR, Stone GW, et al. Relation of admission white blood cell count to long-term outcomes after primary coronary angioplasty for acute myocardial infarction (the stent PAMI trial). Am J Cardiol 2002;91:729-31.